Project development teams: a novel mechanism for accelerating translational research

The trend in conducting successful biomedical research is shifting from individual academic labs to coordinated collaborative research teams. Teams of experienced investigators with a wide variety of expertise are now critical for developing and maintaining a successful, productive research program. However, assembling a team whose members have the right expertise requires a great deal of time and many resources. To assist investigators seeking such resources, the Indiana Clinical and Translational Sciences Institute (Indiana CTSI) created the Project Development Teams (PDTs) program to support translational research on and across the Indiana University-Purdue University Indianapolis, Indiana University, Purdue University, and University of Notre Dame campuses. PDTs are multidisciplinary committees of seasoned researchers who assist investigators, at any stage of research, in transforming ideas/hypotheses into well-designed translational research projects. The teams help investigators capitalize on Indiana CTSI resources by providing investigators with, as needed, mentoring and career development; protocol development; pilot funding; institutional review board, regulatory, and/or nursing support; intellectual property support; access to institutional technology; and assistance with biostatistics, bioethics, recruiting participants, data mining, engaging community health, and collaborating with other investigators.Indiana CTSI leaders have analyzed metrics, collected since the inception of the PDT program in 2008 from both investigators and team members, and found evidence strongly suggesting that the highly responsive teams have become an important one-stop venue for facilitating productive interactions between basic and clinical scientists across four campuses, have aided in advancing the careers of junior faculty, and have helped investigators successfully obtain external funds

Advancing medical technology innovation and clinical translation via a model of industry-enabled technical and educational support: Indiana Clinical and Translational Sciences Institute’s Medical Technology Advance Program

The success rate for translation of newly engineered medical technologies into clinical practice is low. Traversing the “translational valleys of death” requires a high level of knowledge of the complex landscape of technical, ethical, regulatory, and commercialization challenges along a multi-agency path of approvals. The Indiana Clinical and Translational Sciences Institute developed a program targeted at increasing that success rate through comprehensive training, education, and resourcing. The Medical Technology Advance Program (MTAP) provides technical, educational, and consultative assistance to investigators that leverages partnerships with experts in the health products industry to speed progress toward clinical implementation. The training, resourcing, and guidance are integrated through the entire journey of medical technology translation. Investigators are supported through a set of courses that cover bioethics, ethical engineering, preclinical and clinical study design, regulatory submissions, entrepreneurship, and commercialization. In addition to the integrated technical and educational resources, program experts provide direct consultation for planning each phase along the life cycle of translation. Since 2008, nearly 200 investigators have gained assistance from MTAP resulting in over 100 publications and patents. This support via medicine–engineering–industry partnership provides a unique and novel opportunity to expedite new medical technologies into clinical and product implementation

The Access Technology Program of the Indiana Clinical Translational Sciences Institute (CTSI): A model to facilitate access to cutting-edge technologies across a state

Introduction: Access to cutting-edge technologies is essential for investigators to advance translational research. The Indiana Clinical and Translational Sciences Institute (CTSI) spans three major and preeminent universities, four large academic campuses across the state of Indiana, and is mandate to provide best practices to a whole state. Methods: To address the need to facilitate the availability of innovative technologies to its investigators, the Indiana CTSI implemented the Access Technology Program (ATP). The activities of the ATP, or any program of the Indiana CTSI, are challenged to connect technologies and investigators on the multiple Indiana CTSI campuses by the geographical distances between campuses (1–4 hr driving time). Results: Herein, we describe the initiatives developed by the ATP to increase the availability of state-of-the-art technologies to its investigators on all Indiana CTSI campuses, and the methods developed by the ATP to bridge the distance between campuses, technologies, and investigators for the advancement of clinical translational research. Conclusions: The methods and practices described in this publication may inform other approaches to enhance translational research, dissemination, and usage of innovative technologies by translational investigators, especially when distance or multi-campus cultural differences are factors to efficient application

Phosphate nutrition effects on growth, phosphate transporter transcript levels and physiology of alfalfa cells

Phosphorus deficiency reduces forage yield and stand persistence of alfalfa (Medicago sativa L.). Our objectives were to isolate and characterize a high-affinity phosphate-transporter (P-transporter) from alfalfa roots (Medicago sativa L.); determine how phosphorus (P) nutrition impacts P-uptake, growth, and carbohydrate and protein metabolism of alfalfa cells; and learn how expression of the P-transporter is influenced by P nutrition. An 1087-base pair (bp) sequence was isolated using RT-PCR that possessed high nucleotide and amino acid sequence similarity to high-affinity P-transporters. Cultured cells were sampled at 3-day intervals for 9 days while growing in media containing P concentrations ranging from 0 to 10 mM. Media P concentrations declined rapidly in all P treatments by day 6. Low media P concentrations (0, 0.1 and 0.5 mM) reduced cell growth rates compared to higher media P levels (2.5, 5 and 10 mM). Suspension cell cultures supplied 0.5, 2.5, 5, and 10 mM P had lower starch concentrations by day 3 compared to cells cultured in media containing 0 and 0.1 mM P. Steady-state transcript levels for the high-affinity P- transporter were high in P-deprived cells, but declined within 1 day when cells were provided 10 mM P

Exploratory Study on the Foliar Incorporation and Stability of Isotopically Labeled Amino Acids Applied to Turfgrass

There is increasing interest in the use of amino acid-based biostimulant products due to their reported abilities to improve a number of quality characteristics in a variety of specialty crops. However, when it comes to the foliar application of amino acids to turfgrass, there are still many basic questions about their uptake forms and incorporation into cellular metabolism. In this study, we shed light on the fate of amino acids exogenously applied to turfgrass foliage through a series of time-course, isotopic-labeling studies in creeping bentgrass (Agrostis stolonifera L.) leaves. Using both 15N-labeled and 15N,13C double-labeled L-glutamate applied exogenously to creeping bentgrass foliage, we measured the uptake of glutamate and its integration into γ-aminobutyric acid (GABA) and L-proline, two amino acids with known roles in plant stress adaptation. Our results demonstrate that glutamate is rapidly absorbed into creeping bentgrass foliage and that it is utilized to produce GABA and proline. Based on the labeling patterns observed in the endogenous pools of glutamate/glutamine, GABA, and the proline from applied glutamate-[13C515N1], we can further conclude that glutamate is predominantly taken up intact and that mineralization into other forms of nitrogen is a minor fate. Taken together, the collective findings of this study provide evidence that amino acids exogenously applied to turfgrass foliage can be rapidly absorbed, and serve as stable sources of precursor molecules to be integrated into the metabolism of the plant

Proteomic Analysis of 3T3-L1 Adipocytes Treated with Insulin and TNF-α

Insulin resistance is an indication of early stage Type 2 diabetes (T2D). Insulin resistant adipose tissues contain higher levels of insulin than the physiological level, as well as higher amounts of intracellular tumor necrosis factor-α (TNF-α) and other cytokines. However, the mechanism of insulin resistance remains poorly understood. To better understand the roles played by insulin and TNF-α in insulin resistance, we performed proteomic analysis of differentiated 3T3-L1 adipocytes treated with insulin (Ins), TNF-α (TNF), and both (Ins + TNF). Out of the 693 proteins identified, the abundances of 78 proteins were significantly different (p < 0.05). Carnitine parmitoyltransferase-2 (CPT2), acetyl CoA carboxylase 1 (ACCAC-1), ethylmalonyl CoA decarboxylase (ECHD1), and methylmalonyl CoA isomerase (MCEE), enzymes required for fatty acid β-oxidation and respiratory electron transport, and β-glucuronidase, an enzyme responsible for the breakdown of complex carbohydrates, were down-regulated in all the treatment groups, compared to the control group. In contrast, superoxide dismutase 2 (SOD2), protein disulfide isomerase (PDI), and glutathione reductase, which are the proteins responsible for cytoskeletal structure, protein folding, degradation, and oxidative stress responses, were up-regulated. This suggests higher oxidative stress in cells treated with Ins, TNF, or both. We proposed a conceptual metabolic pathway impacted by the treatments and their possible link to insulin resistance or T2D

Reciprocal innovation: A new approach to equitable and mutually beneficial global health partnerships

Global health researchers often discount mutual learning and benefit to address shared health challenges across high and low- and middle-income settings. Drawing from a 30-year partnership called AMPATH that started between Indiana University in the US and Moi University in Kenya, we describe an innovative approach and program for mutual learning and benefit coined ‘reciprocal innovation.’ Reciprocal innovation harnesses a bidirectional, co-constituted, and iterative exchange of ideas, resources, and innovations to address shared health challenges across diverse global settings. The success of AMPATH in Kenya, particularly in HIV/AIDS and community health, resulted in several innovations being ‘brought back’ to the US. To promote the bidirectional flow of learning and innovations, the Indiana CTSI reciprocal innovation program hosts annual meetings of multinational researchers and practitioners to identify shared health challenges, supports pilot grants for projects with reciprocal exchange and benefit, and produces educational and training materials for investigators. The transformative power of global health to address systemic health inequities embraces equitable and reciprocal partnerships with mutual benefit across countries and communities of academics, practitioners, and policymakers. Leveraging a long-standing partnership, the Indiana CTSI has built a reciprocal innovation program with promise to redefine global health for shared wellbeing at a global scale